Business Context and Reporting Period
This Form 8-K was filed by AnaptysBio, Inc. on April 8, 2021. The report discloses a corporate governance event regarding the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the appointment of Oleg Nodelman as a Class I director, effective immediately on April 8, 2021. Mr. Nodelman is the manager and control person of EcoR1 Capital, LLC, an investment adviser to funds that are beneficial owners of more than 5% of the Company's common stock.
Guidance, Outlook, and Risks
- Management Commentary: The Company entered into a standard form of indemnification agreement with Mr. Nodelman.
- Related Party Transactions: There are no arrangements or understandings between Mr. Nodelman and other persons regarding his selection, nor are there family relationships with other directors or officers.
- Risks and Contingencies: No specific risks, contingencies, or unusual items were disclosed in this filing.
Investor Verification Checklist
- Verify the beneficial ownership percentage of EcoR1 Capital, LLC in AnaptysBio, Inc.
- Review the standard form of indemnification agreement previously filed as Exhibit 10.1 to the Form S-1 (September 9, 2015).
- Confirm the absence of other material interests or transactions involving Mr. Nodelman as required by Item 404(a) of Regulation S-K.